Evidence & regulatory context
- Mechanism
- ChEMBL compound_search for 'C-10068' returned 0 hits (explicit negative result). The parent scaffold is the dextromethorphan/morphinan class; DEXTROMETHORPHAN CHEMBL52440 (max_phase 4, first approval 1982, ATC R05DA09 and N07XX59, USAN stem -orphan which explicitly covers deuterated compounds) was retrieved for reference only and is DELIBERATELY NOT recorded as an identity match, because C-10068 is a distinct 3-ethoxy deuterated analogue. ClinicalTrials.gov was NOT queried for this entry within the run budget, so empty trials here is an OMISSION, not a negative finding.
- Target
- Not recorded
- Injury models
- TBI
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatTBIPenetrating / ballisticSprague-DawleyMaleContinuous infusion1.0, 2.5 and 5.0 mg/kg/hStarted after injury
Model: Penetrating ballistic-like brain injury
C-10068 dose-dependently reduced nonconvulsive seizure incidence by 40 to 50%, frequency by 20 to 70% and duration by 30 to 82%, and 5.0 mg/kg/h attenuated hippocampal astrocyte activation and perilesional microglial reactivity, but motor and cognitive function did not improve.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.
